We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 97.34 | 0 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Novartis AG on Monday said the U.S. Food and Drug Administration and the European Medicines Agency accepted the company's applications seeking approval for ofatumumab for the treatment of relapsing forms of multiple sclerosis in adults.
The Swiss drug maker said ofatumumab, if approved, has the potential to become a first-choice treatment for a broad patient population and the first B-cell therapy that can be self-administered at home using an autoinjector pen.
Novartis said the applications are based on Phase III studies in which ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as annualized relapse rate.
Novartis said it expects U.S. regulatory approval for ofatumumab in June and approval in Europe by the second quarter of 2021.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 24, 2020 12:19 ET (17:19 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
